Navigation Links
Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
Date:12/6/2008

SAN FRANCISCO, Dec. 6 /PRNewswire/ -- Researchers today report that after the implementation of Medicare coverage limitations for erythropoiesis-stimulating agents (ESAs), a significantly greater proportion of anemic cancer patients who were on chemotherapy and who received ESAs needed blood transfusions and utilized more units of blood per patient than those patients who received ESAs prior to implementation of coverage limitations. The findings from this observational study will be presented at the 50th Annual Meeting of the American Society of Hematology on Saturday, December 6th at 9:00 a.m. PST.

In July 2007, the Centers for Medicare and Medicaid Services (CMS) issued coverage limitations, in the form of a National Coverage Determination (NCD), for the use of ESAs in anemic cancer patients receiving chemotherapy. An ongoing, prospective, observational study [Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) registry] is evaluating ESA-treated anemic cancer patients receiving chemotherapy. The present analyses were conducted using data from this study, focused on patients covered by Medicare before and after implementation of the CMS NCD for ESAs.

"We wanted to examine the potential impacts on transfusion patterns and hematologic changes in anemic Medicare patients receiving chemotherapy treated with ESAs before and after implementation of the ESA coverage limitations," said study director Chris L. Pashos, PhD, Vice President, Abt Bio-Pharma Solutions, Inc. "Our analyses found increased transfusion rates and greater blood utilization in anemic Medicare patients receiving chemotherapy and treated with ESAs after implementation of the ESA NCD compared with before implementation of the ESA NCD."

Study Methods and Results

Data from 288 Medicare patients (pre-NCD: 230, post-NCD: 58) from 41 sites included in the DOSE registry were analyzed. Data we
'/>"/>

SOURCE Ortho Biotech Products, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
2. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
3. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
4. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
5. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
6. Gene Therapy Corrects Sickle Cell Disease in Laboratory Study
7. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
8. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
9. PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.
10. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger lives ... of the world. As an engineer for the past 20 years, ... of the military service. He,s been to six of the seven ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... Iclaprim also achieved high eradication rates for ... Staphylococcus aureus (MRSA), REINACH, Switzerland, Oct. ... combined results from two pivotal Phase III,clinical ... Antimicrobial Agents,and Chemotherapy (ICAAC)/Infectious Diseases Society of ...
... Paratek Pharmaceuticals, Inc. today,announced positive Phase 2 data ... aminomethylcycline (AMC). The Phase 2 study compared,safety and ... PTK 0796 to,Zyvox(R) in the treatment of patients ... trial met its primary safety and,tolerability endpoint, demonstrating ...
Cached Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:11/28/2014)... 2014 Agein.com, the Internet’s premier anti-aging web ... of the foremost experts in the industry, is releasing its ... this winter. , “The official start of winter is still ... been hit with an icy blast. After one of the ... 2015 will usher in another brutal winter,” says Dr. Kevin ...
(Date:11/28/2014)... Brosix is always making changes to its ... a more efficient, effective, and secure experience. Most recently, ... 1. The ability to setup local servers for each ... service customers around the globe. , 2. The ability ... customers that require millions of users in one network. ...
(Date:11/28/2014)... FL (PRWEB) November 28, 2014 Dr. ... cosmetic dermatologists , announced the addition of Dr. Bridgit ... Nolan joins the practice after having completed her dermatology ... Medicine. , Dr. Walder invited Dr. Nolan ... in medicine, surgery and cosmetic dermatology. Not only does ...
(Date:11/28/2014)... York, New York (PRWEB) November 28, 2014 ... are continuing to move forward in New Jersey’s ... claims in a consolidated litigation established there is ... Case List updated on November 18th shows 1,293 ... was created for lawsuits that allege complications resulting ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Miami's Plastic ... website. Practice founder Dr. Jeffrey Epstein ... Created using a groundbreaking WordPress platform, the site is ... , Currently, up to 75% of all prospective ... ever, these people are logging on with smartphones, tablets, ...
Breaking Medicine News(10 mins):Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Dr. Diane Walder Welcomes New Cosmetic Dermatologist to Practice 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2
... Molecular & Cell Biology at Boston University Henry M. ... at Boston University School of Medicine discovered recently a ... expression. The study describing this work titled, "Mpk1 MAPK ... Termination," appears in the March 4 issue of ...
... new, rapid blood test that could lead to early ... thousands of people stricken with fungal meningitis, a leading ... closer to market with a recent collaboration between the ... "The ability to quickly identify yeast infection in ...
... 4 (HealthDay News) -- Children are more likely to ... playgrounds in their neighborhoods, researchers report. The study ... give their opinions about outdoor public spaces in their ... children spent watching television, using the computer and playing ...
... trial process in the United States is on shaky ... are increasingly defined by specific genetic and biologic markers ... therapies grow smaller and smaller. Coupled with skyrocketing costs ... are essential in bringing new and effective therapies to ...
... THURSDAY, March 3 (HealthDay News) -- More young people are ... engaging in same-sex encounters, according to a new report detailing ... from interviews with 13,500 men and women aged 15 to ... that more than half of young people under age 24 ...
... (HealthDay News) -- The brain,s so-called reward center actually responds ... causing fear, finds a new study in mice. The ... help explain why some people are thrill-seekers. Pleasurable or ... a bridge, can trigger the production of dopamine, a neurotransmitter ...
Cached Medicine News:Health News:Novel mechanism for control of gene expression revealed 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 2Health News:University of Nevada, Reno, teams with IMMY to make new life-saving blood test 3Health News:To bring effective therapies to patients quicker, use the team approach 2Health News:To bring effective therapies to patients quicker, use the team approach 3Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 3
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
Semi-Rigid Ureteroscope...
... ACMI DUR-8 Elite's 8.7 Fr shaft reaches ... comparable scope providing complete intrarenal access, ... smooth, lubricious outer covering and working channel ... And its patented torque-stable shaft construction, tight-bend ...
Medicine Products: